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The mucosal surface of the female genital tract is a complex biosystem, which provides a barrier against the outside world and
participates in both innate and acquired immune defense systems. This mucosal compartment has adapted to a dynamic, non-
sterile environment challenged by a variety of antigenic/inﬂammatory stimuli associated with sexual intercourse and endogenous
vaginal microbiota. Rapid innate immune defenses against microbial infection usually involve the recognition of invading
pathogens by speciﬁc pattern-recognition receptors recently attributed to the family of Toll-like receptors (TLRs). TLRs recognize
conserved pathogen-associated molecular patterns (PAMPs) synthesized by microorganisms including bacteria, fungi, parasites,
andvirusesaswellasendogenousligandsassociatedwithcelldamage.MembersoftheTLRfamily,whichincludes10humanTLRs
identiﬁed to date, recognize distinct PAMPs produced by various bacterial, fungal, and viral pathogens. The available literature
regarding the innate immune system of the female genital tract during human reproductive processes was reviewed in order
to identify studies speciﬁcally related to the expression and function of TLRs under normal as well as pathological conditions.
Increased understanding of these molecules may provide insight into site-speciﬁc immunoregulatory mechanisms in the female
reproductive tract.
1.Introduction
The mucosal surface of the respiratory, gastrointestinal, and
urogenital tracts separates the external environment from
the internal sterile environment and thus represents the
ﬁrst line of defense against microbes. These mucosal innate
systems consist principally of mechanical, chemical, and
cellular components. The ﬁrst of these, the mechanical com-
ponent, primarily carries out the physical barrier function
of the mucosa, but also includes physiological functions
such as cilial action, motility, desquamation, and mucous
secretion. The second component, the chemical component,
can be further divided into three subcomponents: soluble
or cell-associated pattern recognition molecules, proteins,
and peptides, which are responsible for orchestration of
the immune response. The third component of the innate
immune system is the cellular component, which includes
epithelialcells,stromalﬁbroblasts,andvariousinﬂammatory
leukocytes.
Mucosal epithelial cells constitute a crucial part of the
innate immune system and are actively engaged in the ﬁrst
line of defense against microbial infections. Defense at the
epithelial barrier includes the mechanical aspect of prevent-
ing penetration of the structure by microorganisms. The
mucosal epithelial cells are known to function as sentinels
that recognize antigens, and they respond in a manner lead-
ing to bacterial and viral eradication, as well as send signals
to underlying immune cells. When a pathogenic challenge
exceeds the protective capacity of the mucosal epithelial cells,
they trigger a series of alarm signals resulting in the secretion
of chemokines ultimately important for the recruitment of
other components of the innate defense network, which in
turn leads to the development of an acute inﬂammatory
reaction. Binding of a pathogen with the epithelium can
lead to cell death by necrosis, apoptosis, or internalization
of the organism; however, the invading organism may
remain on the cell surface and induce disease from this
location. At this stage, increased vascular permeability2 Mediators of Inﬂammation
leads to extravasation of acute-phase proteins and protein
complement into the damaged tissue. Also aﬀected are the
endothelial adhesion molecules that reduce the activity of
phagocyticgranulocytes,allowingthemtoleavebloodvessels
and be transported along a chemotactic gradient towards
the pathogen. These various steps, which run parallel rather
than in a sequential manner, are controlled by cytokines
secreted from the cellular components (e.g., epithelial cells
and inﬂammatory leukocytes) of the innate system. While
these immediate mechanisms are in progress, antigenic
material is processed by dendritic cells and macrophages
for presentation to T cells, a process which represents the
initiation of the more slowly developing acquired responses.
However, the mechanisms leading to these latter responses
diﬀer in the mucosal linings of diﬀerent organs [1].
The major purpose of the innate immune system is to
react rapidly to infectious agents with the initiation of an
inﬂammatory response, and to form subsequent adaptive
immune responses. After a pathogen makes contact with
the epithelial surface, signals are generated that result in
the production of chemokines, cytokines, prostaglandins,
and leucotrienes by the epithelium, signaling cell injury [2].
However, the pathogen also interacts with other components
of the innate immune system such as dendritic cells and
macrophages. The basis of this activation of the innate
immune system is pattern recognition [3]. Pathogens are
characterized by speciﬁc arrangements of key molecules
called pathogen-associated molecular patterns (PAMPs) and
are recognized by pattern recognition receptors (PRRs).
The PAMPs are vital structures of the microbial cell
that have altered little over evolutionary time spans and
include lipopolysaccharide (LPS), lipoproteins, peptidogly-
can (PGN), lipoarabinomannan, and oligosaccharides. The
PRRs are found on many cells of the innate immune system
including epithelial cells, ﬁbroblasts, and inﬂammatory
leukocytes. There are several diﬀerent families of PRRs such
as scavenger receptors, Toll-like receptors (TLRs), nucleotide
binding oligomerization domain- (NOD-) like recep-
tors, retinoic-acid-inducible protein (RIG)-I-like receptors,
formyl peptide receptors, mannose and glycan receptors,
C-type lectin receptors, complement receptors, and CD14.
Among the PRRs, TLRs are capable of sensing organisms
ranging from bacteria to fungi, protozoa, and viruses, and
they play a major role in innate immunity.
2. StructureandCharacteristicsof
Human Female GenitalMucosa
Thefemalegenitaltractiscomposedofasequenceofcavities.
The external genital tract at the vulva leads into the vagina,
which connects in succession to the uterine cervix, the
endometrium,andthentothefallopiantubes(Figure 1).The
lumen of the lower genital tract (vagina and ectocervix) is
lined with squamous epithelium; whereas the upper genital
tract(endocervix,endometrium,andfallopiantubes)islined
with columnar epithelium. The surface epithelium serves a
critical function, that is, as the defensive front line of the
mucosal innate immune system in the female genital tract.
Uterine corpus
Uterine cervix
Endometrium
Fallopian tube
Ovary
Endocervix
Exocervix
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Figure 1: Structure of the female genital tract.
Under normal conditions, the mucosa of the female genital
tract appears to be in a state of controlled inﬂammation.
Theuppergenitaltractisvirtuallyfreeoforganisms,with
little commensal microbial activity [4]. Recent evidences
suggest that there is a site-speciﬁc mucosal immune system
in the femaleupper genital tract,including the endometrium
and fallopian tubes, which diﬀers from that described for the
intestinal, respiratory, and lower genital tracts. This putative
immune system in the fallopian tubes and endometrium
might contribute to the maintenance of an aseptic milieu,
free of the microorganisms that sporadically colonize the
upper genital tract.It is essential that the mucosal epithelium
of the upper genital tract has the capacity to recognize and
respond to ascending pathogens, while at the same time
avoiding a state of chronic inﬂammation that might disrupt
the epithelial barrier. The upper genital tract is vulnerable
to the spread of microorganisms from the lower genital
tract,resultinginthedevelopmentofinfectiousdiseasessuch
as endometritis and salpingitis [5]. The sequelae of such
chronic inﬂammation of the female genital tract would be
highly detrimental to the host and would include increased
transmission of sexually transmitted diseases [6].
Thecervicalandvaginalepitheliumisconstantlyexposed
to microorganisms including species of commensal as well
as pathogenic organisms; as anaerobic bacterial ﬂora is
normally present in the vagina. Therefore, the mucosal
surface of the lower genital tract represents a complex
biosystem that provides a barrier against the outside world
and participates in both innate and acquired immune
defense systems. This mucosal component has adapted to a
dynamic, nonsterile environment challenged by a variety of
antigenic/inﬂammatory stimuli associated with sexual inter-
course and endogenous vaginal microbiota. The cervicov-
aginal epithelial cells that line the mucosal surface are often
the ﬁrst cells to come into contact with microbial pathogens;
normally there are very few immune cells that present in the
cervicovaginal mucosa and lumen [6, 7]. The cervicovaginal
epithelial cells initiate and coordinate the inﬂammatoryMediators of Inﬂammation 3
response, altering the adjacent epithelium and the under-
lying stromal ﬁbroblasts and immune cells to counter the
potential danger posed by various microorganisms.
3. PatternRecognition via
the TLR System in Humans
Rapid innate immune defenses against microbial infection
usually involve the recognition of invading pathogens by
speciﬁc PRRs recently attributed to the family of TLRs.
TLRs are present in plants, invertebrates, and vertebrates
and they represent a primitive host defense mechanism
against microorganisms [8–11]. As shown in Table 1, TLRs
recognize conserved PAMPs synthesized by microorganisms
including bacteria, fungi, parasites, and viruses as well as
endogenous ligands associated with cell damage, such as
heat-shock protein 60, heat-shock protein 70, polysaccharide
fragments of heparin sulfate, hyaluronic acid, ﬁbrinogen,
ﬁbronectin DA domain, and mRNA [12]. Members of the
TLR family include 10 TLRs identiﬁed in humans thus
far, which recognize distinct PAMPs produced by various
bacterial, fungal, and viral pathogens. The recognition of
bacterial PAMPs (e.g., LPS, PGN, ﬂagellin) is mediated by
TLR1, 2, 4, 5, and 6 [13–16]. Among these TLRs, four are
designed to recognize nucleic acids: TLR3, TLR7, TLR8,
and TLR9 [17–20]. TLR7 and TLR8 recognize nucleotide
derivatives, such as self and viral single-stranded RNA [19,
20], and TLR9 binds unmethylated DNA found in bacteria
[17]. In contrast, TLR3 recognizes double-stranded RNA
(dsRNA) [18], a molecular signature of RNA viruses [21].
Therefore, it is likely that TLR3 plays a physiological role in
antiviral innate immunity [22].
TLRs are transmembrane signaling proteins that are
designed to recognize, with high speciﬁcity, various pro-
teins, lipids, carbohydrates, and nucleic acids of invading
microorganisms. In turn, TLRs activate signaling cascades in
cells that can trigger immune and inﬂammatory responses
to combat the infectious agent [3, 23, 24]. Although every
member of the TLR family responds to a speciﬁc ligand,
they all share strong similarities in terms of their structures
and properties [25]. TLR proteins are located on either the
plasma membrane or internal membranes. Their cytoplas-
mic signaling domain is separated by a single membrane-
spanning domain from the ligand-recognizing extracellular
or luminal domain, which contains multiple repeats of a
leucine-rich repeats (LRRs) motif XXLXLXX. The 19–25
tandem copies of LRRs are thought to provide a highly spe-
ciﬁc binding surface for the cognate ligand. The cytoplasmic
domain of the TLR family shares extensive homology with
that of the interleukin (IL)-1 receptor family and is referred
to as the toll-IL receptor (TIR) domain, which extends to
about 200 residues [26, 27]. Ligand binding to TLRs leads
to a common signal transduction pathway involving TIR,
which couples with adaptor molecules including MyD88
[28] that binds to TLR1, TLR2, TLR4, TLR5, TLR6, TLR7,
TLR8, TLR9, and TLR10 [29–31]; MAL/TIRAP, a MyD88
homologue that binds to TLR1, TLR2, TLR4, and TLR6 [32,
33]; TRAM that binds to TLR4; TRIF/TICAM1 that binds to
Table 1: Human TLRs and their cognate ligands.
TLRs Ligand
TLR1 triacyl lipopeptides, modulin (bacteria)
Pam3Cys-Ser-(Lys)4 (synthetic lipoprotein)
TLR2 peptidoglycan, lipoprotein, lipopeptides,
atypical LPS,
lipoteichoic acid, phenol-soluble modulin
(bacteria)
zymozan, lipoarabinomannan (fungi)
GPI anchors, glycolipids (protozoa)
envelope protein (virus)
Pam3Cys-Ser-(Lys)4 (synthetic lipoprotein)
TLR3 dsRNA (virus)
mRNA (host)
poly (I:C) (synthetic dsRNA)
TLR4 LPS, lipoteichoid acid, mannuronic acid
polymers (bacteria)
mannan, glucoronoxylomannan (fungi)
heat-shock protein 60,
glycoinositolphospholipids (protozoa)
envelope protein, F protein (virus)
heat-shock protein 60, heat-shock protein 70,
polysaccharide fragments of heparin sulfate,
hyaluronic acid, ﬁbrinogen, ﬁbronectin DA
domain (host)
TLR5 ﬂagellin (bacteria)
TLR6 diacyl lipopeptide, modulin, soluble
tuberculosis factor (bacteria)
TLR7 ssRNA (virus)
ssRNA (host)
imidazoquinoline (synthetic antiviral
compound)
loxoribine (guanosine analog)
TLR8 ssRNA (virus)
ssRNA (host)
TLR9 unmethylated CpG DNA (bacteria, protozoa,
virus)
hemozoin (protozoa)
CpG-ODN (synthetic CpG-rich
oligonucleotide)
Chromatin-IgG complex (host)
TLR10 Unknown
TLR3 and TLR4 [34]( Figure 2)[ 28, 29]. There are two main
pathways activated by the TLR family, the MAL/MyD88-
dependent and the MyD88-independent TRAM/TRIF path-
way.SignalingthroughMyD88activatesnuclearfactor(NF)-
κB and induces many cytokines including tumor necrosis
factor (TNF)-α and IL-6. Stimulation of TRIF signaling
pathway activates the interferon (IFN) regulatory factor
(IRF) family to induce production of type I IFNs [35, 36].
Subsequently, a signaling complex is formed that includes
the IL-1 receptor-associated kinases (IRAKs), Tollip and
TNF receptor-associated factor 6 (TRAF-6), transforming4 Mediators of Inﬂammation
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Figure 2: Simpliﬁed diagram of TLR signaling pathways.
growth factor (TGF)-β-activated kinase (TAK1), and the
TAK1 binding proteins TAB1 and TAB2. The formation of
this complex ultimately results in the phosphorylation of the
inhibitor of NF-κB( I κB) and the activation of the NF-κB
pathway[30,31,37].Inthismanner,TLRsregulateanumber
of consequences such the production of proinﬂammatory
cytokines, the upregulation of costimulatory molecules on
antigen-presenting cells, and the maturation of naive den-
dritic cells. TLR binding to microbial ligands is thus a key
step in the acute inﬂammatory response.
It should be noted that cell surface TLRs (TLR1, TLR2,
TLR4, TLR5, and TLR6) appear to recognize microbial
products such as LPS or lipopeptides; whereas intracellular
TLRs (TLR3, TLR7, TLR8, and TLR9) recognize nucleic
acids [28, 29]. The availability of endogenous ligands and
the amount of cell-surface TLRs are both tightly restricted
to maintain suﬃcient TLR responses for the containment
of pathogens, without inducing detrimental responses in
the host. All of the nucleic acid-recognizing TLRs are
expressed on the endosomal membranes of cells, rather than
on plasma membranes; hence, ligand binding by the LRR
motifs of these TLRs occurs in the lumen of intracellular
vesicles. It is generally accepted that the extracellular nucleic
acids released from damaged tissues or cells, infected or
uninfected, are endocytosed and presented to the internal
TLRs. Alternatively, nucleic acids from bacteria or viruses,
whichmultiplywithinacell,canbecapturedinmembranous
vesicles and then transported to TLRs in the endosomes.
ActivationoftheseTLRsleadstotheinductionofinterferons,
proinﬂammatory cytokines, and chemokines. Cell-surface
TLRs also sense endogenous ligands, released in damaged
tissue as a danger signal, resulting in the induction of inﬂam-
mation under both infectious and noninfectious conditions.
In a number of recent studies, TLRs have been found on
a wide range of cells, including immune cells such as mast
cells, macrophages, and dendritic cells. TLRs are also found
on epithelial cells and mesenchymal ﬁbroblasts, and these
cells recognize microbial infections by sampling the exterior
milieuusingagroupofreceptorsthatareabletodiscriminate
between potential pathogens and self-produced molecules.
4. Expressionand Functionof TLRs in
the HumanFemale GenitalTract
4.1. TLR1, TLR2, and TLR6. TLR2 is structurally related
to TLR1 and TLR6 [38]. TLR2 forms heterodimers with
TLR1andTLR6,whichisinvolvedindiscriminatingbetween
the molecular structures of diacyl and triacyl lipopeptides
[39–41]. Complexes of TLR1 and TLR2 recognize various
microbial components, such as lipoproteins/lipopeptides,
lipoarabinomannan, and PGNs from gram-positive and
gram-negative bacteria and mycoplasma [14, 42, 43]. It also
recognizes lipoteichoic acid from gram-positive bacteria, a
phenol-soluble medulin from Staphylococcus aureus,g l y c o l -
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of protozoa [45], and zymosan and phospholipomannan
from fungi [46, 47]. TLR2 is also reported to be involved
in the recognition of atypical LPS from nonenterobacteria,
the structures of which are diﬀerent from the typical LPS of
gram-negative bacteria [44, 48]. Experimentally, TLR2 has
been shown to recognize synthetic lipoproteins [Pam3Cys-
Ser-(Lys)4][ 40]. During microbial infection in the female
genital tract, TLR2 is considered to recognize the PGN of
C. trachomatis [42, 49, 50], LPS and fragments of PGN
of Neisseria gonorrhoeae [51–53], and phospholipomannan
of Candida albicans [54]. TLR2 is also involved in the
recognition of viral components such as cytomegalovirus
and herpes simplex virus type 1 [55–57]. CD36, a member
of the class II scavenger family of proteins, was shown to
serve as a facilitator or coreceptor for diacyl lipopeptide
recognition through the TLR2/6 complex [58]. Both TLR2
and TLR6 are necessary for responding to mycoplasma-
associated protein.
Constitutive TLR1 and TLR6 expression has been
detected in the epithelial cells of the fallopian tubes,
endometrium, endocervix, ectocervix, and vagina [59–67].
TLR1 expression has also been detected in uterine NK
cells [68], vascular endothelial cells, and smooth muscle
cells within the stroma of the cervix and the myometrial
smooth muscle cells of the uterus [63]. Whereas, TLR6
expression was detected in uterine NK cells [51] and in
stromal ﬁbroblasts within the vagina [63].
Constitutive expression of TLR2 has been reported in the
epithelial cells of the fallopian tubes, endometrium, cervix,
and vagina [59, 60, 62–66, 69, 70], smooth muscle cells of
the cervix and vagina [63, 71], endometrial stromal cells
[70], and uterine NK cells [68, 72]. The highest levels of
TLR2 mRNA expression have been observed in the fallopian
tubes and cervical tissues, followed by the endometrium and
ectocervix[60].TheexpressionlevelsofTLR2inendometrial
stromal cells were comparable to those of endometrial
epithelial cells. Signiﬁcantly higher levels of expression of
TLR2 and TLR6 in the endometrium have been observed
during the secretory phase than in other phases of the
menstrual cycle [56, 67, 73]. TNF-α upregulates the TLR2
expression in human cervical smooth muscle cells [71].
Pam3Cys-Ser-(Lys)4, a synthetic analog of bacterial
lipopeptides that bind to TLR2/1 heterodimers, was found to
induce the production of MIP-3αand TNF-α by endometrial
epithelial cells [74]. Polyriboinosinic:polyribocytidylic acid
[poly (I:C)], a TLR3 agonist, induced the expression of
TLR2 in human fallopian tube epithelial cells [65]. FLS-1,
a TLR2/6 heterodimer agonist, induced the expression of
proinﬂammatory cytokines and chemokines in the epithelial
cells of cervix and vagina [66]. Lipoteichoic acid inhibits
human cytomegalovirus infection in ectocervical tissue
through induction of IFN-β production [75]. Mycoplasma
genitalium and the C-terminal portion of the antigenic
protein encoded by MG309 activate NF-κB via TLR2/6,
resulting in cytokine secretion from the epithelial cells of
the uterine cervix and vagina [37]. Whereas, polyanionic
microbicides, such as dextran sulfate and polystyrene
sulfonate inhibits TLR1/2- and TLR2/6-mediated cytokine
production by human cervical and vaginal epithelial cells
[76]. TGF-β is reported to inhibit the TLR-2-mediated
activation of uterine NK cells [72].
4.2. TLR3. TLR3 recognizes dsRNA and is considered to
mediate various antiviral responses. dsRNA during viral
infection can arise from several sources [25]. The genome
of the infecting virion can itself be dsRNA, as in the
case of the known natural dsRNA viruses. However, even
ssRNAvirussamplesoftencontaindefectiveparticlescontain
primarily double-stranded defective genomes. Intracellular
viral dsRNA can be generated in a number of ways. In the
case of ssRNA viruses, the formation of dsRNA replication
intermediates is an obligatory step in viral reproduction.
In the case of DNA viruses, complementary mRNAs are
often produced that are encoded by partially overlapping
genes located on the opposite strands of the viral genome.
Long viral polycistronic mRNAs often contain abundant
stable double-stranded stems. Such ﬁndings, taken together,
have indicated that all viral infections induce dsRNA at
some point during replication [77]. Recently, host-derived
mRNA released by dying or dead cells was shown to activate
TLR3, suggesting that activation via TLR3 can occur in a
variety of situations [78]. It has been demonstrated that a
secondary structure creating hairpin loops within the mRNA
is responsible for TLR3 activation. In addition, TLR3 has
been shown to recognize double-stranded nucleic acid from
Schistosoma mansoni and to be involved in the antiparasite
response [79]. At present, it is generally accepted that RNA
from a number of diﬀerent sources can activate TLR3, as
long as the RNA displays a secondary structure containing
double-stranded regions, provided that the RNA is present
in the appropriate cellular vesicle.
Inexperimentalmodels,poly(I:C),asyntheticanalogof
viral dsRNA, is utilized as a ligand for TLR3 to mimic viral
infection [18, 22, 65, 80, 81]. The induction of TLR3 signal-
ing via dsRNA activates transcription factors such as NF-κB
and IRF3, resulting in the production of proinﬂammatory
and antiviral cytokines and chemokines [18, 82–84]. In the
clinicalsetting,avarietyofviruses(e.g.,herpessimplexvirus,
human papilloma virus, hepatitis B virus, hepatitis C virus,
cytomegalovirus, human immunodeﬁciency virus, etc.) can
be the causative of viral infection in the female genital tract.
Constitutive expression of TLR3 has been reported
in female genital tissue samples from fallopian tubes,
endometrium,cervix,andvagina[60,65,66].Theexpression
of TLR3 in the endometrium is signiﬁcantly higher during
the secretory phase than in other phases of the menstrual
cycle [67, 83]. TLR3 expression has been detected in
the epithelial cells of the fallopian tubes, endometrium,
endocervix, ectocervix, and vagina [59, 62–65, 70, 84–
87]. TLR3 expression was also detected in endometrial
stromal cells, although expression levels were higher in
endometrial epithelial cells than in endometrial stromal
cells [70]. Jorgenson et al. [85] recently demonstrated the
cycle-dependent expression of TLR3 in primary endometrial
epithelial cells. TLR3 expression was also detected in the
stromal ﬁbroblasts of the vagina and endocervix [63], and
in human uterine NK cells [68, 72].6 Mediators of Inﬂammation
Poly (I:C), a TLR3 agonist, induces the expression
of proinﬂammatory cytokines, chemokines, and TLR3 in
human fallopian tube epithelial cells [65, 87]. Cultured
fallopiantubeepithelialcellsrecognizeviraldsRNAviaTLR3
and secrete proinﬂammatory cytokines and chemokines via
an NF-κB-mediated signal pathway [87]. Poly (I:C) alone
does not stimulateIFN-γ production byIL-2-expanded uter-
ine NK cells [88]. Whereas, the presence of autologous uter-
ine macrophages led to a signiﬁcant increase in IFN-γ pro-
duction by IL-2-expanded uterine NK cells [88]. Whereas,
polyanionic microbicides, such as dextran sulfate and
polystyrene sulfonate, inhibit TLR3-mediated cytokine pro-
duction by human cervical and vaginal epithelial cells [76].
It has been demonstrated that human endometrial
epithelial cells recognize dsRNA and produce proinﬂam-
matory cytokines and chemokines via a TLR3-mediated
pathway [64, 85, 89]. Lesmeister et al. [90] showed that
in vitro treatment of endometrial epithelial cell lines with
17β-estradiol had no eﬀect on TLR3 expression, and
treatment with 17β-estradiol suppressed the production of
proinﬂammatory cytokines and chemokines resulting from
TLR3 stimulation with poly (I:C); these ﬁndings suggest
that 17β-estradiol modulates TLR3 function. Poly (I:C)
also upregulated the production of IL-8 by the epithelial
cells of the uterine cervix [66, 86] and the production of
proinﬂammatory cytokines and chemokines by the epithelial
cells of the vagina [66]. In addition, Poly (I:C) activated
these cells and induced IFN-γ production [75]. TGF-β was
shown to inhibit the TLR-3-mediated activation of uterine
NK cells [91]. Poly (I:C) inhibits human cytomegalovirus
infection in ectocervical tissue through induction of IFN-β
production [75].
4.3. TLR4. LPS is a cell-wall component of gram-negative
bacteria. LPS is composed of lipid A (endotoxin), core
oligosaccharide, and O-antigen. TLR4 recognizes lipid A of
LPS. In addition to bacterial LPS, TLR4 also recognizes heat-
shock protein 60, glycoinositolphospholipids of protozoa
[45], and viral envelope proteins [92–94]. The ligation of
TLR4, in association with the accessory molecules MD-
2 and CD14, leads to the recruitment of MyD88, the
phosphorylation of IL-1 receptor-associated kinase, the
oligomerization of TNF receptor-associated factor 6, and the
subsequent degradation of IκB[ 30, 31]. These events lead to
the activation of NF-κB, and to the resultant transcription of
immune response genes, suchas proinﬂammatory cytokines,
chemokines, and costimulatory molecules, which are nec-
essary for further immune responses [8, 95, 96]. The host
responsetoaprimarybacterialinfectionofamucosalsurface
is acute inﬂammation and is characterized by the inﬁltration
of neutrophils and monocytes. In the clinical setting, a
variety of microorganism-derived substances including LPS
derived from N. gonorrhoeae [51–53], LPS and heat shock
protein derived from C. trachomatis [97, 98], and mannan
derived from C. albicans [54] are putative ligands for TLR4
in the female genital tract.
Constitutive expression of TLR4 was reported in the
following female genital tissues: the fallopian tubes, the
endometrium, the cervix, and the vagina [60, 66]. TLR4
expression has been shown to decline progressively along
the genital tract, with the highest levels of expression in
the fallopian tubes and endometrium, followed by the
cervix [60]. The expression of TLR4 in the endometrium
is signiﬁcantly higher during the secretory phase compared
with that in other phases of the menstrual cycle [67, 83].
Conﬂicting ﬁndings regarding the expression of TLR4 in
the epithelial cells of the female genital tract have been
reported. Some authors’ groups have reported the presence
of TLR4 in the epithelial cells of the fallopian tubes [63,
65], endometrium [62–64, 70, 99], endocervix [63, 66],
and vagina [57, 66]. However, other authors have observed
an absence of TLR4 in the epithelial cells of the fallopian
tubes [100], endocervix [59], ectocervix [59, 63], and vagina
[59, 63]. The expression of TLR4 has also been detected
in endometrial stromal cells [70], myometrial cells [101],
uterine NK cells [68, 72] ,a n ds m o o t hm u s c l ec e l l so fu t e r i n e
cervix [71]. Levels of expression of TLR4 were found to
be higher in endometrial stromal cells than in endometrial
epithelial cells [70].
CD14, a coreceptor of TLR4 for the recognition of LPS,
is not expressed in human fallopian tube epithelial cells or
stromal cells [100]. However, CD14 has been detected in
endometrialstromalﬁbroblasts,althoughitwasnotfoundin
endometrial epithelial cells [99]. Whereas, Herbst-Kralovetz
et al. [66] demonstrated the expression of CD14 in the
epithelial cells of cervix and vagina. CD14 is known to be
expressed in human cervical smooth muscle cells [71]. MD2,
an accessory molecule of TLR4-signaling, was found to be
absent from cultured epithelial cells derived from samples of
normal human vagina, endocervix, and ectocervix [59].
Binding to LPS, a TLR4 ligand, rapidly leads to NF-κB
activation and cytokine expression via TLR4-mediated sig-
naling in fallopian tube stromal ﬁbroblasts [100]. However,
fallopian tube epithelial cells that lack TLR4 do not respond
to LPS. LPS was shown to stimulate the expression of IL-8
in endometrial epithelial cells and stromal ﬁbroblasts via a
TLR4-mediated pathway [99]. LPS also induced the produc-
tion of MIP-3α in primary endometrial epithelial cells [74],
but not in an endometrial epithelial cell line, HHUA [102]. It
has been demonstrated that cultured endocervical epithelial
c e l l sw e r eu n r e s p o n s i v et oL P Sf r o me i t h e rN. gonorrhoeae
or Escherichia coli [59]. LPS induced the translocation of
the NF-κB p65 subunit in human myometrial cells via a
TLR4-protein kinase ζ-mediated pathway [101]. IFN-γ was
also found to enhance the expression of TLR4, CD14, MD2,
and MyD88 in endometrial stromal ﬁbroblasts [99]. LPS
inhibits human cytomegalovirus infection in ectocervical
tissue through induction of IFN-β production [75].
4.4. TLR5. TLR5 recognizes ﬂagellin, a protein component
of bacterial ﬂagella [15]. It has been suggested that TLR5
serves as a sensor for pathogenic bacteria that is able to cross
the epithelium [103].
TLR5 expression has been demonstrated in epithelial
cells derived from the fallopian tubes, endometrium, vagina,
endocervix, and ectocervix [59–65]. TLR5 expression wasMediators of Inﬂammation 7
also detected in smooth muscle cells and vascularendothelial
cells within the stroma of the vagina and endocervix [63].
However, TLR5 expression was not detected in human
uterine NK cells [68]. The expression of TLR5 in the
endometrium is signiﬁcantly higher during the secretory
phase than during other phases of the menstrual cycle
[67, 83].
Flagellin, a TLR5 agonist, induced the expression of
proinﬂammatory cytokines and chemokines in the epithelial
cells of cervix and vagina [66].
4.5. TLR7. TLR7 has been shown to recognize self- and
guanosine- or uridine-rich viral ssRNA from viruses such as
HIV, vesicular stomatitis virus, and inﬂuenza virus [19, 20].
TLR7 signaling is also induced by low molecular-weight
antiviral compounds, that is, imidazoquinolines [104].
TLR7 expression has been detected in the epithelial cells
of fallopian tubes, endometrium, cervix, and vagina [61, 65,
66, 84, 105]. TLR7 expression was also detected in uterine
NK cells [68] and in the endometrial stroma [69].
Poly (I:C), a TLR3 agonist, was shown to induce the
expression of TLR7 in human fallopian tube epithelial cells
[65]. Imiquimod, a TLR7 agonist, was demonstrated to
stimulate IL-8 production by the primary cultured cells
isolatedfromfallopiantube,endometrium,andcervix[105].
4.6. TLR8. TLR8 has been shown to recognize both self- and
guanosine- or uridine-rich viral ssRNA from viruses such as
HIV, vesicular stomatitis virus, and inﬂuenza virus [19, 20,
106].
TLR8 is expressed in the epithelial cells of fallopian
tubes, endometrium, cervix, and vagina [61, 63–65, 73, 86,
105]. TLR8 expression was also detected in the endometrial
stroma, as determined by immunohistochemical analysis
[73]. However, no TLR8 expression has been detected in
human uterine NK cells [66]. CL075, a TLR8 agonist, was
demonstrated to stimulate IL-8 production by the primary
cultured cells isolated from fallopian tube, endometrium,
and cervix [105].
4.7. TLR9. TLR9 recognizes DNA containing unmethylated
deoxytidyl-phosphate-deoxyguanosine (CpG) motifs com-
mon to both bacterial and viral genomes [17, 104, 107].
CpG motifs are found in the genomes of DNA viruses
such as herpes simplex virus [108–110], suggesting that
TLR9 induces antiviral responses in herpes genitalis. TLR9
also recognizes nonDNA pathogenic components, such as
hemozoinandgenomicDNAderivedfromprotozoamalarial
parasites [43, 111]. Experimentally, TLR9 signaling has also
been induced by synthetic CpG-rich oligonucleotides (CpG-
ODN) [17].
TLR9 expression has been reported in fallopian tube,
endometrium, and cervix [105]. TLR9 expression has been
demonstrated in epithelial cells of the fallopian tube,
endometrium, cervix, and vagina [61, 62, 64–66, 70, 73, 86].
TLR9 expression was also detected in endometrial stromal
cells [70, 73]. The authors of the latter study noted observ-
ing comparable expression levels of TLR9 in endometrial
epithelial cells and stromal cells. However, higher levels of
expression of TLR9 in the endometrium have been reported
during the secretory phase than during other phases of the
menstrual cycle [67, 73]. Moreover, TLR9 expression was
absent in human uterine NK cells [68].
CpG oligodinucleotides upregulated the production of
IL-8 by the epithelial cells of the fallopian tube and uterine
cervix [65, 86]. CpG oligodinucleotides, a TLR9 agonist, was
demonstrated to stimulate IL-8 production by the primary
cultured cells isolated from fallopian tube, endometrium,
and cervix [105]. To date, therehavebeen no studies of TLR9
expression in the vaginal mucosa. CpG oligodinucleotides
inhibit human cytomegalovirus infection in ectocervical
tissue through induction of IFN-β production [75].
4.8. TLR10. A speciﬁc ligand for TLR10 has yet to be
identiﬁed [23, 112, 113]. TLR10 expression has been
demonstrated in fallopian tube, but not in endometrium
or cervix [105]. TLR10 expression is absent in human
endometrial epithelial cells and endometrial epithelial cell
lines [60, 64]. However, Aﬂatoonian et al. [73] demonstrated
using immunohistochemistry that TLR10 is expressed in
the endometrial epithelium and stroma. The same authors
also reported that levels of expression of TLR10 in the
endometrium are signiﬁcantly higher during the secretory
phase than during other phases of the menstrual cycle [73].
TLR10 expression has also been detected in human uterine
NK cells [68]. TLR10 has not been detected in human
fallopiantubeepithelialcells[65].Higherlevelsofexpression
of TLR9 in the endometrium have been reported during the
secretory phase than during the proliferative phase of the
menstrual cycle [67].
5. Conclusions
It has been suggested that there is a site-speciﬁc mucosal
immune system in the female upper genital tract that diﬀers
from that described in the gastrointestinal and respiratory
tracts [114]. Furthermore, the immune system in the upper
genital tract diﬀers from that of the lower genital tract.
T h ep u t a t i v ei m m u n es y s t e mi nt h eu p p e rg e n i t a lt r a c t
appears to contribute to the maintenance of an aseptic
milieu; that is, this immune system inhibits the growth of
microorganisms that sporadically colonize this region [4].
In contrast, the lower genital tract is constantly exposed
to microorganisms, including species of commensal as well
as pathogenic organisms; in general, abundant anaerobic
bacterial ﬂora is known to be present in the vagina. The
mucosal components of the lower genital tracts have adapted
to a dynamic, nonsterile environment challenged by a variety
of antigenic/inﬂammatory stimuli associated with sexual
intercourse and endogenous vaginal microbiota. Clearly, it
is essential that these mucosal tissues develop mechanisms
forselectivelyrespondingtopathogens,whilesimultaneously
avoiding chronic inﬂammation due to immune responses
to commensal microorganisms [5]. The sequelae of a
chronic inﬂammation in the female genital tract would be8 Mediators of Inﬂammation
highly detrimental to the host and would include increased
transmission of sexually transmitted diseases [6].
As summarized in this paper, the innate immune system
in the female genital tract is highly complex and multi-
factorial. Mucosal epithelial cells, ﬁbroblasts, lymphocytes,
macrophages, and dendritic cells associated with the female
genital tract have evolved a unique mechanism for the
recognition of pathogens. These cells express a variety of
TLRs, allowing them to recognize the diﬀerent repertoire of
a wide range of PAMPs. It is likely that TLR distribution in
the female genital tract reﬂects an immunological tolerance
of commensal organisms in the lower portions of the tract
(i.e., vagina, ectocervix, and to some extent, the endocervix),
as well as an intolerance of commensal microbial ﬂora
in the upper portion of the tract (i.e., the endometrium
and fallopian tubes). The mucosal surface of the upper
portion of the female genital tract is generally considered
a sterile site, in part due to the cervical mucus, which
ﬁlters bacteria and other debris. However, this barrier can
readily be crossed by a variety of infectious agents, typically
leading to endometritis and salpingitis. Thus, it is essential
that the upper genital tract epithelium has the capacity
to recognize and respond to ascending pathogens while
simultaneouslyavoidingastateofunnecessaryinﬂammation
that might disrupt the epithelial barrier. The sequelae of
such inﬂammation in the upper genital tract would be highly
detrimental to the defense and reproductive functions of the
mucosal surface. If the luminal epithelial barrier is broken
by acute inﬂammation, damaged epithelial cells initiate and
coordinate the inﬂammatory response, alerting adjacent
epithelium and underlying immune cells of the potential
danger posed by various microorganisms.
STDs are a major worldwide health problem that com-
promise reproductive fecundity and cut short the lives of
millions of men, women, and children [115, 116]. Despite
extensive eﬀorts, only limited success has been achieved in
dealing with STDs such as N. gonorrhoeae, C. trachomatis,
group B streptococcus, herpes simplex virus type 2, and
HIV.Thesepathogenic organismscanbe recognized byTLRs
expressed in the female genital tract. Further investigation
intoTLRsignalinginthesetissuescouldprovidenewinsights
into the roles played by the immune system in maintaining
health and combating STDs and other genital infectious
diseases.
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